Mainz Biomed Bv Stock Beneish M Score

MYNZ Stock  USD 0.90  0.03  3.45%   
This module uses fundamental data of Mainz Biomed to approximate the value of its Beneish M Score. Mainz Biomed M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out Mainz Biomed Piotroski F Score and Mainz Biomed Altman Z Score analysis.
  
At this time, Mainz Biomed's Net Debt is fairly stable compared to the past year. Long Term Debt is likely to rise to about 1 M in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 4.1 M in 2024. At this time, Mainz Biomed's Debt To Equity is fairly stable compared to the past year.
At this time, it appears that Mainz Biomed BV is an unlikely manipulator. The earnings manipulation may begin if Mainz Biomed's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Mainz Biomed executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Mainz Biomed's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-5.31
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables

0.74

Focus
Asset Quality

0.67

Focus
Expense Coverage

0.97

Focus
Gross Margin Strengs

1.05

Focus
Accruals Factor

0.97

Focus
Depreciation Resistance

0.97

Focus
Net Sales Growth

0.68

Focus
Financial Leverage Condition

1.56

Focus

Mainz Biomed Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Mainz Biomed's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Net Receivables178.3 K354.5 K
Way Down
Slightly volatile
Total Revenue611.1 K895.5 K
Way Down
Slightly volatile
Total Assets10.4 M15.4 M
Way Down
Slightly volatile
Total Current Assets8.2 MM
Significantly Down
Slightly volatile
Non Current Assets Total6.8 M6.4 M
Sufficiently Up
Slightly volatile
Property Plant Equipment367.4 K388.4 K
Notably Down
Slightly volatile
Depreciation And Amortization909.7 K866.4 K
Sufficiently Up
Slightly volatile
Selling General Administrative8.9 M13.4 M
Way Down
Slightly volatile
Total Current Liabilities9.7 M9.2 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total2.7 M2.9 M
Moderately Down
Slightly volatile
Short Term Debt5.5 M5.2 M
Sufficiently Up
Slightly volatile
Long Term DebtMM
Fairly Up
Slightly volatile

Mainz Biomed BV Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Mainz Biomed's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Mainz Biomed in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Mainz Biomed's degree of accounting gimmicks and manipulations.

About Mainz Biomed Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation And Amortization

909,733

At this time, Mainz Biomed's Depreciation And Amortization is fairly stable compared to the past year.

About Mainz Biomed Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Mainz Biomed BV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mainz Biomed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mainz Biomed BV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Mainz Biomed BV offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mainz Biomed's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mainz Biomed Bv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mainz Biomed Bv Stock:
Check out Mainz Biomed Piotroski F Score and Mainz Biomed Altman Z Score analysis.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for Mainz Stock analysis

When running Mainz Biomed's price analysis, check to measure Mainz Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mainz Biomed is operating at the current time. Most of Mainz Biomed's value examination focuses on studying past and present price action to predict the probability of Mainz Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mainz Biomed's price. Additionally, you may evaluate how the addition of Mainz Biomed to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Transaction History
View history of all your transactions and understand their impact on performance
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Stocks Directory
Find actively traded stocks across global markets
Is Mainz Biomed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mainz Biomed. If investors know Mainz will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mainz Biomed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.62)
Revenue Per Share
0.055
Quarterly Revenue Growth
0.111
Return On Assets
(0.93)
Return On Equity
(3.03)
The market value of Mainz Biomed BV is measured differently than its book value, which is the value of Mainz that is recorded on the company's balance sheet. Investors also form their own opinion of Mainz Biomed's value that differs from its market value or its book value, called intrinsic value, which is Mainz Biomed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mainz Biomed's market value can be influenced by many factors that don't directly affect Mainz Biomed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mainz Biomed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mainz Biomed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mainz Biomed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.